ANI PHARMACEUTICALS, INC Comprehensive Income
ANI PHARMACEUTICALS, INC (ANIP) reported Comprehensive Income of $23.91 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:ComprehensiveIncomeNetOfTax · last filed 2026-08-07
- ANI PHARMACEUTICALS, INC comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-06-30 was $23.91M, a 189.72% increase year-over-year.
- ANI PHARMACEUTICALS, INC comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-03-31 was $28.94M, a 107.49% increase year-over-year.
- ANI PHARMACEUTICALS, INC comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-12-31 was $25.71M.
- ANI PHARMACEUTICALS, INC comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-09-30 was $26.12M.
- ANI PHARMACEUTICALS, INC comprehensive income (loss), net of tax, attributable to parent for fiscal 2025 was $74.03M.
- ANI PHARMACEUTICALS, INC comprehensive income (loss), net of tax, attributable to parent for fiscal 2024 was -$22.04M, a 242.46% decline from fiscal 2023.
- ANI PHARMACEUTICALS, INC comprehensive income (loss), net of tax, attributable to parent for fiscal 2023 was $15.47M.
- ANI PHARMACEUTICALS, INC comprehensive income (loss), net of tax, attributable to parent for fiscal 2022 was -$32.67M.
| Period end | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 3 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 6 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 9 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | $23.91M 10-Q · filed 2026-08-07 | $52.84M 10-Q · filed 2026-08-07 | $78.56M derived: sum of 3 quarters · filed 2026-08-07 | $104.67M derived: sum of 4 quarters · filed 2026-08-07 |
| 2026-03-31 | $28.94M 10-Q · filed 2026-05-08 | $54.65M derived: sum of 2 quarters · filed 2026-05-08 | $80.77M derived: sum of 3 quarters · filed 2026-05-08 | $89.02M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-12-31 | $25.71M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $51.83M derived: sum of 2 quarters · filed 2026-02-27 | $60.08M derived: sum of 3 quarters · filed 2026-08-07 | $74.03M 10-K · filed 2026-02-27 |
| 2025-09-30 | $26.12M 10-Q · filed 2025-11-07 | $34.37M derived: sum of 2 quarters · filed 2026-08-07 | $48.31M 10-Q · filed 2025-11-07 | $38.02M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-06-30 | $8.25M 10-Q · filed 2026-08-07 | $22.20M 10-Q · filed 2026-08-07 | $11.90M derived: sum of 3 quarters · filed 2026-08-07 | -$15.23M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-03-31 | $13.95M 10-Q · filed 2026-05-08 | $3.65M derived: sum of 2 quarters · filed 2026-05-08 | -$23.48M derived: sum of 3 quarters · filed 2026-05-08 | -$26.84M derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | -$10.30M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | -$37.43M derived: sum of 2 quarters · filed 2026-02-27 | -$40.79M derived: sum of 3 quarters · filed 2026-02-27 | -$22.04M 10-K · filed 2026-02-27 |
| 2024-09-30 | -$27.13M 10-Q · filed 2025-11-07 | -$30.49M derived: sum of 2 quarters · filed 2025-11-07 | -$11.74M 10-Q · filed 2025-11-07 | -$15.80M derived: sum of 4 quarters · filed 2026-02-27 |
| 2024-06-30 | -$3.37M 10-Q · filed 2025-08-08 | $15.39M 10-Q · filed 2025-08-08 | $11.33M derived: sum of 3 quarters · filed 2026-02-27 | $21.62M derived: sum of 4 quarters · filed 2026-02-27 |
| 2024-03-31 | $18.76M 10-Q · filed 2025-05-09 | $14.69M derived: sum of 2 quarters · filed 2026-02-27 | $24.98M derived: sum of 3 quarters · filed 2026-02-27 | $33.82M derived: sum of 4 quarters · filed 2026-02-27 |
| 2023-12-31 | -$4.07M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $6.22M derived: sum of 2 quarters · filed 2026-02-27 | $15.06M derived: sum of 3 quarters · filed 2026-02-27 | $15.47M 10-K · filed 2026-02-27 |
| 2023-09-30 | $10.29M 10-Q · filed 2024-11-08 | $19.13M derived: sum of 2 quarters · filed 2024-11-08 | $19.53M 10-Q · filed 2024-11-08 | $17.42M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-06-30 | $8.84M 10-Q · filed 2024-08-06 | $9.24M 10-Q · filed 2024-08-06 | $7.13M derived: sum of 3 quarters · filed 2025-02-28 | $3.14M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-03-31 | $403.00K 10-Q · filed 2024-05-10 | -$1.71M derived: sum of 2 quarters · filed 2025-02-28 | -$5.70M derived: sum of 3 quarters · filed 2025-02-28 | -$17.91M derived: sum of 4 quarters · filed 2025-02-28 |
| 2022-12-31 | -$2.11M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | -$6.11M derived: sum of 2 quarters · filed 2025-02-28 | -$18.31M derived: sum of 3 quarters · filed 2025-02-28 | -$32.67M 10-K · filed 2025-02-28 |
| 2022-09-30 | -$3.99M 10-Q · filed 2023-11-08 | -$16.20M derived: sum of 2 quarters · filed 2023-11-08 | -$30.56M 10-Q · filed 2023-11-08 | -$53.52M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-06-30 | -$12.21M 10-Q · filed 2023-08-09 | -$26.57M 10-Q · filed 2023-08-09 | -$49.52M derived: sum of 3 quarters · filed 2024-02-29 | -$52.77M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-03-31 | -$14.36M 10-Q · filed 2023-05-08 | -$37.32M derived: sum of 2 quarters · filed 2024-02-29 | -$40.57M derived: sum of 3 quarters · filed 2024-02-29 | -$55.08M derived: sum of 4 quarters · filed 2024-02-29 |
| 2021-12-31 | -$22.96M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | -$26.20M derived: sum of 2 quarters · filed 2024-02-29 | -$40.71M derived: sum of 3 quarters · filed 2024-02-29 | -$34.22M 10-K · filed 2024-02-29 |
| 2021-09-30 | -$3.25M 10-Q · filed 2022-11-09 | -$17.76M derived: sum of 2 quarters · filed 2022-11-09 | -$11.27M 10-Q · filed 2022-11-09 | -$13.23M derived: sum of 4 quarters · filed 2023-03-09 |
| 2021-06-30 | -$14.51M 10-Q · filed 2022-08-08 | -$8.02M 10-Q · filed 2022-08-08 | -$9.98M derived: sum of 3 quarters · filed 2023-03-09 | -$8.61M derived: sum of 4 quarters · filed 2023-03-09 |
| 2021-03-31 | $6.49M 10-Q · filed 2022-05-10 | $4.53M derived: sum of 2 quarters · filed 2023-03-09 | $5.90M derived: sum of 3 quarters · filed 2023-03-09 | -$8.79M derived: sum of 4 quarters · filed 2023-03-09 |
| 2020-12-31 | -$1.96M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | -$589.00K derived: sum of 2 quarters · filed 2023-03-09 | -$15.29M derived: sum of 3 quarters · filed 2023-03-09 | -$29.11M 10-K · filed 2023-03-09 |
| 2020-09-30 | $1.37M 10-Q · filed 2021-11-01 | -$13.32M derived: sum of 2 quarters · filed 2021-11-01 | -$27.15M 10-Q · filed 2021-11-01 | -$30.82M derived: sum of 4 quarters · filed 2022-03-15 |
| 2020-06-30 | -$14.70M 10-Q · filed 2021-08-06 | -$28.52M 10-Q · filed 2021-08-06 | -$32.19M derived: sum of 3 quarters · filed 2022-03-15 | -$29.32M derived: sum of 4 quarters · filed 2022-03-15 |
| 2020-03-31 | -$13.83M 10-Q · filed 2021-05-07 | -$17.50M derived: sum of 2 quarters · filed 2022-03-15 | -$14.63M derived: sum of 3 quarters · filed 2022-03-15 | -$10.86M derived: sum of 4 quarters · filed 2022-03-15 |
| 2019-12-31 | -$3.67M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | -$798.00K derived: sum of 2 quarters · filed 2022-03-15 | $2.97M derived: sum of 3 quarters · filed 2022-03-15 | $1.60M 10-K · filed 2022-03-15 |
| 2019-09-30 | $2.87M 10-Q · filed 2020-11-05 | $6.64M derived: sum of 2 quarters · filed 2020-11-05 | $5.27M 10-Q · filed 2020-11-05 | $9.79M derived: sum of 4 quarters · filed 2021-03-11 |
| 2019-06-30 | $3.77M 10-Q · filed 2020-08-06 | $2.40M 10-Q · filed 2020-08-06 | $6.92M derived: sum of 3 quarters · filed 2021-03-11 | $12.27M derived: sum of 4 quarters · filed 2021-03-11 |
| 2019-03-31 | -$1.37M 10-Q · filed 2020-05-07 | $3.15M derived: sum of 2 quarters · filed 2021-03-11 | $8.50M derived: sum of 3 quarters · filed 2021-03-11 | $11.49M derived: sum of 4 quarters · filed 2021-03-11 |
| 2018-12-31 | $4.52M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-11 | $9.87M derived: sum of 2 quarters · filed 2021-03-11 | $12.87M derived: sum of 3 quarters · filed 2021-03-11 | $15.12M 10-K · filed 2021-03-11 |
| 2018-09-30 | $5.35M 10-Q · filed 2019-11-06 | $8.35M derived: sum of 2 quarters · filed 2019-11-06 | $10.60M 10-Q · filed 2019-11-06 | $968.00K derived: sum of 4 quarters · filed 2020-02-27 |
| 2018-06-30 | $2.99M 10-Q · filed 2019-08-07 | $5.24M 10-Q · filed 2019-08-07 | -$4.39M derived: sum of 3 quarters · filed 2020-02-27 | $334.00K derived: sum of 4 quarters · filed 2020-02-27 |
| 2018-03-31 | $2.25M 10-Q · filed 2019-05-09 | -$7.38M derived: sum of 2 quarters · filed 2020-02-27 | -$2.66M derived: sum of 3 quarters · filed 2020-02-27 | $22.00K derived: sum of 4 quarters · filed 2020-02-27 |
| 2017-12-31 | -$9.63M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | -$4.91M derived: sum of 2 quarters · filed 2020-02-27 | -$2.23M derived: sum of 3 quarters · filed 2020-02-27 | -$1.08M 10-K · filed 2020-02-27 |
| 2017-09-30 | $4.72M 10-Q · filed 2018-11-06 | $7.40M derived: sum of 2 quarters · filed 2018-11-06 | $8.55M 10-Q · filed 2018-11-06 | |
| 2017-06-30 | $2.68M 10-Q · filed 2018-08-07 | $3.83M 10-Q · filed 2018-08-07 | ||
| 2016-12-31 | $3.93M 10-K · filed 2019-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |